Ultrasound company SonoSite Inc. (NSDQ:SONO) added two new med-tech veterans to its executive team this week.
On Tuesday the Bothell, Wash.-based company announced the appointment of Brian Noyes to VP of marketing for North and South America.
The Medical Device Business Journal — Medical Device News & Articles | MassDevice
Ultrasound company SonoSite Inc. (NSDQ:SONO) added two new med-tech veterans to its executive team this week.
On Tuesday the Bothell, Wash.-based company announced the appointment of Brian Noyes to VP of marketing for North and South America.
Fresenius Medical Care (NYSE:FMS) wants a Colorado court to order one of its suppliers, Magnum Plastics, to cover the costs of a recall and any settlements it has to pay as a result, saying Magnum breached its contract when it produced the defective component that led to the recall.
According to the lawsuit, filed in the U.S. District Court for Colorado, Magnum discovered a flaw in the mold it used to produce a component for the Fresenius Liberty hemodialysis system.
GE Healthcare (NYSE:GE) filed the first module of its pre-market approval application for the breast tomosynthesis option of its Senographe Essential system.
The health care giant said the first submission included a device description and non-clinical information, including "phantom testing," and detector performance evaluation. The system is intended as an add-on option for the Senographe Essential to produce 3D images for screening and diagnosis of breast cancer.
Shares of Becton Dickinson (NYSE:BDX) slipped 4.4 percent today after the company announced a 24.4 percent profit slide and missed Wall Street’s expectations for its Q4 earnings.
BD posted profits of $300.0 million, or $1.36 per share, on sales of $2.05 billion for the three months ended Sept. 30. That compares with profits of $396.7 million, or $1.68 per share, on sales of $1.87 billion during the same period last year.
Lumbar spine surgery company TranS1 Inc. (NSDQ:TSON) priced a public offering of 6.2 million shares of common stock at $3.25 per share, expecting to raise up to $20.2 million.
TranS1 plans to use the funds for additional clinical trials, reimbursement efforts, sales personnel, research and product development activities and working capital, according to SEC filings. It added that funds may go toward acquisition of or investment in technologies, products or assets that complement the business.
Date: Wednesday, September 14, 2011, 3:38pm EDT
Moody’s Investors Service has assigned a definite Ba2 rating to about $960 million in bonds issued by finance companies wholly owned by Fresenius Medical Care AG & Co. KGaA (NYSE: FMS), a Germany-based global provider of dialysis services.
The company’s North American operations are headquartered in Waltham, Mass.
Fresenius Medical Care AG (NYSE:FMS) posted a healthy quarter with growth in sales and earnings driven by a 26 percent bump in international sales.
"We are particularly pleased with the success of our international region, given a persistently challenging business environment with the current debt crisis worldwide and the successful expansion of our clinic network in Asia-Pacific and Europe," CEO Dr. Ben Lipps said in prepared remarks.
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This latest feature of MassDevice.com’s coverage highlights our three biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you’re still in the know with Massdevice +3.
Fresenius Medical Care AG (NYSE:FMS) had an active day on the M&A trail, announcing two deals worth a combined $2.1 billion that should bolster the company’s presence in the U.S.
The German dialysis giant, which houses its U.S. headquarters in Waltham, Mass., said it will pay $1.7 billion to acquire Liberty Dialysis Holdings Inc., a privately held company out of Mercer Island, Washington, which was owned by two private equity firms KRG Capital Partners and Bain Capital.